Surrozen, Inc.
SRZNHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Surrozen, Inc. focuses on Biotechnology services and products. Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. The $268.7M market capitalization puts SRZN squarely in micro-cap range for its industry. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Market Cap
$268.7M
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
-5.81
EPS (TTM)
$-36.59
EPS (Fwd)
$-3.98
ROE
—
ROA
-22.8%
Cash
$106.9M
Total Debt
$6.8M
Free CF
-$26.1M
52W Change
178.5%
Annual Financials
Cash vs Debt
Surrozen, Inc. holds $106.9M in cash against $6.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$26.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
SRZN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, SRZN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SRZN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.